Researchers at Foshan Ionova Biotherapeutics Co. Ltd. and Shenzhen Ionova Life Science Co. Ltd. have disclosed fused heterocyclic compounds acting as RAS modulators reported to be useful for the treatment of cancer.

Prelude Therapeutics Inc. has described cyclin dependent kinase (CDK) inhibitors reported to be useful for the treatment of cancer.

Cgenetech (Suzhou, China) Co. Ltd. has divulged cyclopropanamide-containing compounds acting as Janus kinase (JAK) inhibitors, particularly JAK2 and/or JAK1 and/or JAK3, reported to be useful for the treatment of rheumatoid arthritis, ulcerative colitis, atopic dermatitis, systemic lupus erythematosus, essential thrombocythemia, polycythemia vera and myelofibrosis.

Novartis AG has identified spirocyclic piperidinyl derivatives acting as complement factor B (CFB) inhibitors reported to be useful for the treatment of age-related macular degeneration (AMD), diabetic retinopathy and eye disorders.

Terran Biosciences Inc. has synthesized 5-HT2A receptor agonists reported to be useful for the treatment of anxiety, Alzheimer's disease, stroke, rheumatoid arthritis, neurodegeneration, mood disorders, menopause, substance abuse and dependence, among others.

Astrazeneca AB has disclosed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked...

Researchers at 3D Medicines (Beijing) Co. Ltd. and 3D Medicines Inc. have divulged GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer.

Sichuan Good Doctor Panxi Pharmaceutical Co. Ltd. has identified polypeptides reported to be useful for the treatment of inflammatory bowel disease, ulcerative colitis, and dysbacteriosis.

Biogen Inc. has synthesized 3-β-hydroxysteroid-δ(8),δ(7)-isomerase (EBP) inhibitors reported to be useful for the treatment of multiple sclerosis (MS).

Bakx Therapeutics Inc. and Ipsen Pharma SA have disclosed apoptosis regulator BAX activators reported to be useful for the treatment of cancer.